Investors Alert: Lead Plaintiff Opportunity in Intellia Therapeutics Securities Fraud Case Approaching Deadline
Investors in Intellia Therapeutics Inc., a leader in gene-editing technology, face a looming deadline to secure their position as lead plaintiffs in a securities fraud lawsuit alleging the company made misleading statements that adversely impacted shareholder values. The lawsuit, which is gaining momentum, centers around accusations that the Cambridge, Massachusetts-based biotech firm did not fully disclose operational and developmental setbacks during its recent trials, potentially violating federal securities laws. Originally filed in the United States District Court for the Northern District of California, the class-action suit represents investors who purchased shares in Intellia between May … Read more